Alan Moore

Alan Moore is responsible for commercial activities supporting biopharmaceutical products and advanced therapies such as cell and genetic therapies. Previously he oversaw cGMP-compliant contract manufacturing of innovative cell and gene therapies for WuXi AppTec, Inc., as well as supported strategic biopharmaceutical clients. He held positions of increasing responsibility at BioReliance Corp. (Microbiological Associates) leading to Director of Business Development. He served as President of Genzyme Transgenics Washington Laboratories, and Senior Regulatory Coordinator for Genzyme Corporation supporting products such as Carticel®, Epicel®, Cerezyme® , and later as Vice President of Biopharmaceutical Development Services at Genzyme Corporation. Prior to joining WuXi AppTec, Mr. Moore served as Executive Vice President and Chief Business Officer at Althea Technologies, a leading provider of innovative technologies along with manufacturing and aseptic fill and finish services. Mr. Moore has presented on biopharmaceutical, cell and gene therapy development and safety to the U.S. FDA Center for Biologics Evaluation and Research, various U.S. FDA Advisory Committees, Health Protection Branch, Drugs Directorate (Canada), Therapeutic Goods Administration (Australia), Japan Health Science Council (Ministry of Health), and the U.K. Xenotransplantation Interim Regulatory Authority (UKXIRA).